Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidanc...(lts. These measures are also considered ...)

The non GAAP measures are presented in this press release as the Company's management believe that they will provide investors with a means of evaluating, and an understanding of how Shire's management evaluates, the Company's performance and results on a comparable basis that is not otherwise apparent on a US GAAP basis, since many one-time, infrequent or non-cash items that the Company's management believe are not indicative of the core performance of the business may not be excluded when preparing financial measures under US GAAP.

These non GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.

The following are trademarks either owned or licensed by Shire Limited or companies within the Shire group which are the subject of trademark registrations in certain territories, or which are owned by third parties as indicated and referred to in this press release:

Shire Product Active ingredient

ADDERALL(R) XR (mixed salts of a single-entity amphetamine)

AMIGAL(TM) (migalastat hydrochloride) (trademark of

Amicus Therapeutics ("Amicus"))

CALCICHEW(R) range (calcium carbonate with or without Vitamin D3)

CARBATROL (carbamazepine - extended-release capsules)

COMBIVIR (R) (lamivudine) (trademark of GlaxoSmithKline

("GSK"))

DAYTRANA(TM) (methylphenidate transdermal system)

DYNEPO(R) (epoetin delta) (trademark of Sanofi-Aventis)

ELAPRASE(R) (idursulfase)

EPIVIR (R) (lamivudine) (trademark of GSK)

EPZICOM(R)/KIVEXA
'/>"/>